Xenios

1 known investors

Xenios develops extracorporeal membrane oxygenation (ECMO) and extracorporeal life support (ECLS) technologies for patients with cardiac and/or pulmonary failure. The company provides integrated solutions that combine cardiac and pulmonary support on a single platform for critical care physicians.